SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:gup.ub.gu.se/307007"
 

Search: id:"swepub:oai:gup.ub.gu.se/307007" > Adjuvant Olaparib f...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Tutt, A. N. J. (author)

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/307007
  • https://gup.ub.gu.se/publication/307007URI
  • https://doi.org/10.1056/NEJMoa2105215DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:146816442URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival. RESULTS A total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P<0.001). The 3-year distant disease-free survival was 87.5% in the olaparib group and 80.4% in the placebo group (difference, 7.1 percentage points; 95% CI, 3.0 to 11.1; hazard ratio for distant disease or death, 0.57; 99.5% CI, 0.39 to 0.83; P<0.001). Olaparib was associated with fewer deaths than placebo (59 and 86, respectively) (hazard ratio, 0.68; 99% CI, 0.44 to 1.05; P=0.02); however, the between-group difference was not significant at an interim-analysis boundary of a P value of less than 0.01. Safety data were consistent with known side effects of olaparib, with no excess serious adverse events or adverse events of special interest. CONCLUSIONS Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Garber, J. E. (author)
  • Kaufman, B. (author)
  • Viale, G. (author)
  • Fumagalli, D. (author)
  • Rastogi, P. (author)
  • Gelber, R. D. (author)
  • de Azambuja, E. (author)
  • Fielding, A. (author)
  • Balmana, J. (author)
  • Domchek, S. M. (author)
  • Gelmon, K. A. (author)
  • Hollingsworth, S. J. (author)
  • Korde, L. A. (author)
  • Linderholm, Barbro,1959Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xlibar (author)
  • Bandos, H. (author)
  • Senkus, E. (author)
  • Suga, J. M. (author)
  • Shao, Z. (author)
  • Pippas, A. W. (author)
  • Nowecki, Z. (author)
  • Huzarski, T. (author)
  • Ganz, P. A. (author)
  • Lucas, P. C. (author)
  • Baker, N. (author)
  • Loibl, S. (author)
  • McConnell, R. (author)
  • Piccart, M. (author)
  • Schmutzler, R. (author)
  • Steger, G. G. (author)
  • Costantino, J. P. (author)
  • Arahmani, A. (author)
  • Wolmark, N. (author)
  • McFadden, E. (author)
  • Karantza, V. (author)
  • Lakhani, S. R. (author)
  • Yothers, G. (author)
  • Campbell, C. (author)
  • Geyer, C. E. (author)
  • Olympi, A. Clinical Trial Steering (author)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper, Avdelningen för onkologi (creator_code:org_t)

Related titles

  • In:New England Journal of Medicine384:25, s. 2394-24050028-4793
  • In:The New England journal of medicine384:25, s. 2394-24051533-4406

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view